n-Lorem Makes Ultrarare Disease Treatment Personal
Joe Gleeson, MD
n-Lorem Makes Ultrarare Disease Treatment Personal
The nonprofit s founder pauses briefly at their one-year anniversary to reflect on hyper-personalized medicine without taking his eyes off the future.
April 15, 2021
Retirement typically means more time for traveling, hobbies, and relaxation. For Stan Crooke, MD, PhD, it means something very different. Crooke, the founder and executive chairman of Ionis Pharmaceuticals, having served as CEO for more than 30 years, will officially retire this year. Instead of hitting the golf course, he is throwing himself into the foundation he and his wife, Rosanne Crooke, PhD, started just over one year ago the n-Lorem foundation. The foundation’s goal is to provide free, individualized, antisense oligonucleotide (ASO) treatments to patients living with ultrarare (1 to 30 patients worldwide) diseases for life. The funding for n-Lorem comes from the Crookes, Ionis, Biogen, a